LTCG’s Cognitive Testing Tool Administered to Over 1,000,000 Individuals

Company reaches key milestone in the early identification of cognitive impairment

EDEN PRAIRIE, Minn.--()--LTCG, the recognized leader in business process outsourcing for long term care insurance, has now administered its proprietary cognitive screening test to more than 1,000,000 individuals nationwide. LTCG’s Minnesota Cognitive Acuity Screen (MCAS) is a proven and highly accurate assessment tool that detects the earliest forms of cognitive impairment with sensitivities of 97.5% and specificity of 98.5%.

Cognitive impairment can be an indicator of Mild Cognitive Impairment (MCI) or even more serious issues such as Alzheimer’s type dementia. Long term care and life insurers have long relied on the MCAS’s ability to proactively screen for cognitive impairment, as the MCAS provides important insight to support decisions for underwriting and furnishes information critical to the effective management of long term care and disability claims. In fact, today’s milestone is the result of LTCG providing assessment services to more than 50 insurance company clients, including the nation’s largest long term care and life insurers. In addition, new applications for the MCAS have recently emerged, especially among payers serving Medicaid, Medicare and dual eligible populations, as part of transition care and care management programs for individuals with complex or chronic health conditions.

The MCAS can be performed in about 12-15 minutes either in person or over the phone and has been scientifically validated to be a comprehensive screen as it evaluates multiple cognitive domains. It is an effective underwriting tool used to detect early cognitive impairment and is also a valid instrument for documenting moderate-to-severe cognitive impairment in long term care and disability claims.

“The objective information provided by MCAS can help insurers make sound clinical and financial decisions,” said Dr. Stephen Holland, Chief Medical Officer of LTCG. “Having reached the 1,000,000 mark for this screening is truly a testament to how confident our customers are in the accuracy, protective value and reliability of the MCAS.”

According to the Alzheimer’s Association, more than six million Americans are living with cognitive impairment, and that number is expected to grow to over 15 million by 2050. At the same time, a growing body of research shows that mild cognitive impairment and dementia have a substantial impact on care costs throughout life and on life expectancy itself. As a result, screening tools like the MCAS are incredibly useful for long term care, life and disability insurers looking to identify early indicators of cognitive impairment as well as moderate-to-severe cognitive impairment at time of claim.

About LTCG

LTCG is a leading provider of business process outsourcing to the insurance industry, with an emphasis on supporting long term care products. LTCG serves over 50 insurers, including all of the top ten carriers in the long-term care market. The company offers complete administrative support including application processing, underwriting, policy administration and claims and care management as well as health and functional assessments. In addition, LTCG provides clients with unique insight about risk management built upon the industry’s largest database of long term care underwriting and claims outcomes. For more information, visit www.ltcg.com.

About LTCG’s industry-leading MCAS tool

The MCAS was developed and statistically validated in a 1999 blinded trial by a team of physicians and scientists, as well as in university-based blinded trials each year since 2009. Ongoing research at Brown University and a growing body of peer-reviewed literature has validated the ability of the MCAS to detect mild cognitive impairment, early dementia, functional decline and excess mortality. And, the MCAS has been selected both for use in the National Institute of Health and Brown University’s Rhode Island Alzheimer Prevention Registry. In addition, results from research using LTCG’s MCAS have been featured and presented at a number of national and international scientific meetings.

Contacts

LTCG
Adam Hoffman, 317-706-8118
adam.hoffman@ltcg.com

Contacts

LTCG
Adam Hoffman, 317-706-8118
adam.hoffman@ltcg.com